21DRA090: A Phase 1a/1b Study of LY3537982 Administered to Patients with KRAS G12C-Mutant Advanced Solid Tumors

Principal Investigator

Konstantin Dragnev

Study Number

STUDY02001090

Summary

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Phase

I

Contact

Nerissa Charland

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms